1.79 USD
▲-0.03+3.78%
2026-08-03
市值
$165.93M
市盈率
—
EPS
-0.65
股息率
—
52 周区间
1.17 – 2.62
成交量
2.34K
Beta
0.88
目标价
6.00
52W 低 1.1752W 高 2.62
价格走势
公司简介
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking ant...